Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634192 | 0.85 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL5633725 | 0.77 | CACNA2D1 (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL5634353 | 0.76 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL5634479 | 0.74 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL5686065 | 0.71 | SOS1 (0.43) | SOS1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL5633511 | 0.70 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL7382308 | 0.70 | SLC6A4 (0.41) | HTR2AHRH1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5635010 | 0.69 | OPRD1 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5633551 | 0.68 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL5633162 | 0.68 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | claimed |
| JP-2006526000-A | — | — | 2006-11-16 | — | — | JP | claimed |
| EP-1633343-A1 | 3-AMINOMETHYL-PYRROLIDINES AS N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Technologies, Inc. (CA) | 2006-03-15 | — | — | EP | claimed |
| US-20050014748-A1 | N-type calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-01-20 | — | — | US | claimed |
| WO-2004105750-A1 | 3-AMINOMETHYL-PYRROLIDINES AS N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014748-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1I | SOS1 4283/4885HTR2A 455/4885HRH1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.